Core Viewpoint - Recently, Chongqing Laimei Pharmaceutical Co., Ltd. announced that its subsidiary Sichuan Yingrui Pharmaceutical Technology Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of its innovative anti-cancer drug "Nano Carbon Iron Suspension Injection" in combination with standard radiotherapy for solid tumor patients [2] Company Summary - Laimei Pharmaceutical's subsidiary, Sichuan Yingrui, has developed an innovative anti-cancer drug [2] - The drug has received a clinical trial approval notification from the National Medical Products Administration [2] - The clinical trials will focus on the use of the drug in conjunction with standard radiotherapy for patients with solid tumors [2]

Group 1 - The core point of the article is that Zhongheng Group announced the approval of a clinical trial for an innovative anti-cancer drug, "Nano Carbon Iron Suspension Injection," by the National Medical Products Administration of China [2] - The drug is developed by Sichuan Yingrui Pharmaceutical Technology Co., Ltd., a subsidiary of Chongqing Laimei Pharmaceutical Co., Ltd., which is a holding subsidiary of Zhongheng Group [2] - The clinical trial will investigate the combination of Nano Carbon Iron with standard radiotherapy in patients with solid tumors [2]

证券日报网讯12月4日，莱美药业（300006）在互动平台回答投资者提问时表示，截至2025年11月28 日，公司股东户数为33303户。 ...

Core Viewpoint - The company has received ethical approval for the development of Mabalosavir tablets, which is expected to advance clinical trials in accordance with national regulations by June 2025 [1] Group 1 - The company has commissioned an external organization to develop the Mabalosavir tablet project [1] - The clinical trials for Mabalosavir tablets will be conducted in an orderly manner following national clinical trial regulations [1] - The company will continue to monitor the progress of the Mabalosavir tablet clinical trials and fulfill information disclosure obligations as required [1]

Group 1 - China Pacific Insurance has received approval from the financial regulatory authority for Wang Yuhua to serve as a director [1] - Shanghai Bank announced that the regulatory authority has approved Chen Lei's qualification as vice president [2] - Shanghai HuGong has decided to terminate the "Aerospace Equipment Manufacturing Base" fundraising project due to significant changes in project feasibility [3] Group 2 - Dongwang Times plans to reduce its stake by up to 1.20% through share sales [4] - Zhinancun intends to increase its capital by 100 million yuan in its wholly-owned subsidiary, Maigao Securities [5] - Jinxinnong reported a sales revenue of 115 million yuan from pig sales in November [6] Group 3 - Tiantan Biological has completed the Phase III clinical trial of its human prothrombin complex, showing good efficacy and safety for hemophilia B patients [7] - Beijete's subsidiary has signed a framework agreement for equity acquisition to gain control of Yunnan Wenye Nonferrous Metals [8] - Zhongsheng Pharmaceutical's RAY1225 injection has received approval for a new clinical trial indication for treating metabolic-associated fatty liver disease [9] Group 4 - Enhua Pharmaceutical's hydrochloride sulpiride tablets have passed the consistency evaluation for generic drugs [10] - Shenkong Co. plans to invest 60 million yuan in a semiconductor industry fund [11] - Lianhuan Pharmaceutical's subsidiary has received approval for its drug to pass the consistency evaluation for generic drugs [12] Group 5 - Dazhong Transportation has received approval to issue debt financing tools totaling 4.5 billion yuan [13] - Jintian Titanium Industry plans to invest 50 million yuan in an industry merger and acquisition fund [14] - Changchun Gas has committed over 1.7 billion yuan to gas facility upgrades [15] Group 6 - Laimei Pharmaceutical's innovative anti-cancer drug "Nano Carbon Iron" has received approval for clinical trials [16] - Longquan Co. has signed supply contracts worth approximately 50.76 million yuan for nuclear power components [17] - Igor plans to distribute a cash dividend of 1 yuan per 10 shares [18] Group 7 - Xingfa Group's subsidiary has signed a processing agreement for 80,000 tons of lithium iron phosphate [20] - Yunjigroup's director Wang Wanfeng has resigned for personal reasons [21] - Saiseng Pharmaceutical's application for the listing of a new drug has been accepted by the regulatory authority [22] Group 8 - Xinhua Medical has obtained registration certificates for two new medical devices [23] - Chaoying Electronics plans to invest 100 million USD in its Thai subsidiary for an AI circuit board expansion project [24] - Suzhou Planning's application to acquire 100% of Dongjin Aviation has been accepted by the Shenzhen Stock Exchange [25]

Core Viewpoint - Zhongheng Group's subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its innovative anti-cancer drug, "Nano Carbon Iron Suspension Injection," to conduct clinical trials in solid tumor patients [1] Group 1 - The drug is set to be tested in conjunction with standard radiotherapy [1] - The approval marks a significant step in the development of new cancer treatments by the company [1]

Core Viewpoint - Laimei Pharmaceutical's subsidiary, Sichuan Yingrui Pharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its innovative anti-cancer drug, "Nano Carbon Iron Suspension Injection," in combination with standard radiotherapy for solid tumor patients [1] Group 1 - The approved clinical trial aims to further validate the safety and potential efficacy of the "Nano Carbon Iron + Radiotherapy" combination therapy [1] - The trials will be initiated at multiple clinical centers, focusing on solid tumors that are difficult to treat locally [1] - The objective is to explore the clinical value of the combination therapy while ensuring safety [1]

Core Viewpoint - Lai Mei Pharmaceutical's subsidiary Yingrui Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its innovative anti-cancer drug, "Nano Carbon Iron Suspension Injection" [2] Group 1: Product Development - The new generation nano drug, Nano Carbon Iron, is developed based on the existing Nano Carbon Suspension Injection, utilizing Fe2+ as the active anti-cancer ingredient [2] - Nano Carbon serves as a carrier for Fe2+, and the drug exerts its anti-cancer effects by regulating the ferroptosis pathway [2] Group 2: Clinical Trials - The second phase of clinical trials for Nano Carbon Iron is progressing smoothly, with some patient enrollments already completed [2] - There are currently no similar products on the market or in late-stage research [2]

智通财经APP讯，莱美药业(300006.SZ)发布公告，近日，公司控股子公司四川瀛瑞医药科技有限公司 (简称"瀛瑞医药")自主研发的创新抗癌药物"纳米炭铁混悬注射液"(简称"纳米炭铁")获国家药品监督管理 局签发《药物临床试验批准通知书》，同意纳米炭铁联合标准放疗在实体瘤患者中开展临床试验。 本次获批的临床试验将进一步验证"纳米炭铁+放疗"联合方案的安全性和潜在疗效，陆续在多个临床中 心启动"纳米炭铁+放疗"研究，重点关注局部治疗难度较大的实体瘤，以期在确保安全性的前提下，进 一步探索联合疗法的临床价值。 ...

证券代码：300006 证券简称：莱美药业 公告编号：2025-057 重庆莱美药业股份有限公司 2、申请人：四川瀛瑞医药科技有限公司 3、适应症：实体瘤 4、注册分类：化学药品 2 类 5、受理号：CXHL2501026 近日，重庆莱美药业股份有限公司（以下简称"公司"或"莱美药业"）控 股子公司四川瀛瑞医药科技有限公司（以下简称"瀛瑞医药"）自主研发的创新 抗癌药物 "纳米炭铁混悬注射液" （以下简称"纳米炭铁"）获国家药品监督 管理局签发《药物临床试验批准通知书》，同意纳米炭铁联合标准放疗在实体瘤 患者中开展临床试验。现将相关情况公告如下： 一、药品基本情况 1、药品名称：纳米炭铁混悬注射液 6、通知书编号：2025LP03253 7、审批结论：纳米炭铁混悬注射液符合药品注册的有关要求，同意本品联 合标准放疗在实体瘤患者中开展临床试验。 二、药品的其他相关情况 纳米炭铁是在公司产品纳米炭混悬注射液基础上研究开发的新一代纳米药 物，以 Fe 2+作为抗癌有效成分，纳米炭作为 Fe 2+的载体，通过调控铁死亡通路发 挥抗癌作用。纳米炭铁通过瘤内注射，具有抑制肿瘤生长的功能。纳米炭铁是一 种新机理抗癌药物，与 ...